CFCM INTELLIGENCE

Understand what changes.
Know what is established.

Technology, reagents, companies and regulation — tracked through dated events, primary sources and explicit evidence boundaries.

Technology Watch

Platforms, software and changing capabilities.

Reagent Watch

Clones, formats, intended use and availability.

Company Watch

Portfolios, partnerships and market presence.

Regulatory Watch

Primary documents, jurisdictions and effective dates.

Published signals

Only records released through the current editorial workflow appear here. Dates describe the underlying event and source, not the date CFCM discovered it. Independent scientific review is not implied unless explicitly stated.

No market records have completed editorial review yet.

Technology

Velociraptor compares cell populations across cytometry platforms

Velociraptor compares cell populations across cytometry platforms. Research comparisons do not establish prospective clinical diagnostic validation.

Event date

September 10, 2026

Source publication date

September 10, 2026

Research method. This summary establishes neither clinical device authorisation nor commercial availability.

Read the evidence →

velociraptor-cross-platform-cytometry-2026-09-10

Company

Sysmex Europe and Cytek build a tiered clinical-flow workflow across more than a dozen European countries

Sysmex Europe and Cytek Biosciences announced a strategic collaboration across more than a dozen European countries, pairing Sysmex PS-10 automated sample preparation and XF-1600 routine clinical flow cytometry with Cytek Northern Lights-CLC spectral flow cytometry. The public announcement does not identify the participating countries, so Spain-specific inclusion remains unverified.

Event date

September 9, 2026

Source publication date

September 9, 2026

More than a dozen European countries; Spain specifically not verified in the public announcement

Strategic collaboration announced. Sysmex XF-1600 and PS-10 are positioned within Sysmex's clinical flow portfolio. Cytek states that Northern Lights-CLC and certain reagents are available for clinical use in the European Union and China; other Cytek products are RUO unless otherwise specified.

Read the evidence →

sysmex-cytek-europe-clinical-flow-collaboration-2026-09-09

Regulatory

MDCG revision 5 clarifies IVDR Rule 7 for control materials

Revision 5 updates the Rule 7 rationale and examples.

Event date

September 9, 2026

Source publication date

September 9, 2026

EU

Published non-binding guidance; no new statutory effective date inferred

Read the evidence →

mdcg-2020-16-rev5-rule7-2026-09-09

Reagent

Slingshot launches ViaComp Ultra XT; Amine variant is catalogued as RUO

The manufacturer announced the ViaComp Ultra XT family on 17 August 2026 and stated it was shipping.

Event date

August 17, 2026

Source publication date

August 17, 2026

US manufacturer catalogue; EU supply unconfirmed

Manufacturer-reported shipping; product labelled Research Use Only

Read the evidence →

viacomp-ultra-xt-launch-2026-08-17

Regulatory

Zenbexus FDA label names Hematogenix NGF in MRD efficacy evidence

FDA granted accelerated approval to the specified iberdomide combination on 13 August 2026.

Event date

August 13, 2026

Source publication date

August 13, 2026

US

Accelerated drug approval; assay clearance or approval not established

Read the evidence →

zenbexus-hematogenix-ngf-label-2026-08-13

Technology

Eveo: announcement and planned order timeline

Manufacturer announcement with a planned order timeline; current availability remains unconfirmed.

Event date

March 16, 2026

Source publication date

March 16, 2026

Availability jurisdiction not established

announced; September 2026 order-taking was planned, but current opening of orders is not confirmed from a newer primary source as of 4 October 2026

Read the evidence →

eveo-announcement-march-2026

Company

300K-funded Salamanca project evaluates freeze-dried blood for CLL

The University of Salamanca lists a CLL blood preservation validation project running from 1 December 2025 to 30 November 2026, led by Alberto Orfao and funded by 300K Solutions.

Event date

December 1, 2025

Source publication date

Spain

Project scheduled through 30 November 2026; results and indication-specific regulatory status not established here

Read the evidence →

300k-funded-salamanca-project-evaluates-freeze-dried-blood-for-cll

Technology

ICCS 2026 adds an analytical-performance poster to CellMek SPS dry-tube automation

Beckman Coulter lists an ICCS 2026 poster on analytical performance of an automated dry-tube workflow using CellMek SPS, adding conference evidence to its existing dry-reagent automation platform.

Event date

Source publication date

ICCS 2026, Miami, USA / product availability jurisdiction-specific

Existing CellMek SPS platform with dry-reagent module; the poster is included in the ICCS 2026 program. The listing does not verify a completed presentation day or analytical results. LUCID custom panels are RUO; product/use status is jurisdiction-specific.

Read the evidence →

iccs-2026-cellmek-sps-dry-tube-automation

Technology

ICCS 2026 lists a label-free foundation model for automated viability in imaging flow cytometry

Waters Biosciences lists an ICCS 2026 poster on a label-free foundation model for automated viability assessment and functional assays in imaging flow cytometry. CFCM publishes the signal as WATCH because the public conference page does not disclose model-development or external-validation details.

Event date

Source publication date

ICCS 2026, Miami, USA / global research market

Included in the ICCS 2026 program in an RUO imaging-flow ecosystem. The listing does not verify an exact completed presentation day, diagnostic AI authorization or clinical performance.

Read the evidence →

iccs-2026-label-free-foundation-model-imaging-flow-2026-10-06

Technology

ICCS 2026 tests CellView imaging as a single-cell check for rare plasma-cell MRD events

Waters Biosciences lists an ICCS 2026 poster using CellView imaging to verify the single-cell origin of rare abnormal plasma-cell events in measurable residual disease research. CFCM publishes the signal as WATCH because public conference material does not yet provide diagnostic-performance data.

Event date

Source publication date

ICCS 2026, Miami, USA / global RUO research market

Included in the ICCS 2026 program on the FACSDiscover A8/CellView research platform. The listing does not verify a completed presentation day. The A8/CellView platform is Research Use Only; the poster does not establish diagnostic authorization.

Read the evidence →

iccs-2026-cellview-plasma-cell-mrd-single-cell-2026-10-06

Technology

ICCS 2026 puts flow-cytometry-based genotyping beside phenotypic MRD workflows

The Beckman Coulter ICCS 2026 program includes phenotypic flow cytometry and superRCA flow-cytometer-based genotyping as parallel MRD research workflows.

Event date

Source publication date

ICCS 2026, Miami, USA / global research market

Included in the ICCS 2026 program; relevant research workflow components are labelled Research Use Only. An exact completed presentation date is not established by the program.

Read the evidence →

iccs-2026-flow-cytometry-genotyping-superrca

Reagent

ICCS 2026 puts therapy-aware flow reagents in focus: CD38(VHH) JK36 and TRBC2

Beckman Coulter's ICCS 2026 poster programme highlights RUO reagent strategies for difficult interpretation contexts: CD38(VHH) clone JK36 for CD38 detection in the presence of anti-CD38 therapy and TRBC1/TRBC2 conjugates for T-cell clonality research. These are not new product launches.

Event date

Source publication date

Global RUO catalogue; ICCS presentation in Miami, USA

CD38(VHH)-Alexa Fluor 488 clone JK36 and TCR Cβ2 (TRBC2)-APC clone SAM.2 are catalogued as Research Use Only. ICCS poster presence does not change regulatory status.

Read the evidence →

beckman-therapy-aware-reagents-iccs-2026

Technology

Curiox reports lower operator- and site-dependent variability with automated antibody cocktailing at ICCS 2026

Curiox reports ICCS 2026 poster data on the Pluto Antibody Cocktailing Wizard across 9-, 10- and 24-colour panels. The company reports lower operator/site variability and reduced hands-on time. CFCM publishes the signal as WATCH because the evidence is manufacturer-generated poster data rather than independent clinical validation.

Event date

Source publication date

ICCS 2026, Miami / online; product market status not reclassified from this poster

Existing Curiox Pluto automation platform. This record concerns new manufacturer-generated performance data, not a new regulatory authorization or product launch.

Read the evidence →

curiox-pluto-antibody-cocktailing-iccs-2026

Company

Challenbio manufacturer profile: international presence claims need confirmation

The manufacturer website lists conventional and full-spectrum cytometry, automated preparation and reagents.

Event date

Source publication date

China; Europe and North America - manufacturer claims

Manufacturer profile observed; Spanish commercial presence unverified

Read the evidence →

challenbio-international-profile-watch

TECHNOLOGY WATCH

From specifications to useful performance

Announcements, independent evidence and clinical validation are assessed separately.

Read the CFCM analysis →

REAGENT WATCH

Reagents in clinical context

Identity, clone, catalogue number and jurisdiction matter when interpreting a product update.

Explore antibody selection →

COMPANY WATCH

Market presence needs evidence

A distributor listing, a conference presentation and clinical authorisation describe different developments.

Read the market analysis →

REGULATORY WATCH

Start with intended purpose

Track the authority, document, jurisdiction and effective date before drawing operational conclusions.

Read the regulatory analysis →

How CFCM evaluates a signal

Primary evidence → What it demonstrates → Evidence boundary → Practical implications → CFCM view.

Manufacturer statements are identified as such. Unknown dates and unconfirmed availability remain unknown. Editorial priority is separate from publication approval.

Editor, affiliation and independence →

From a development to a laboratory question

Use the clinical resources to test the interpretation behind a technology or reagent claim. Discuss defined technical content or a disclosed sponsorship brief when appropriate.